Saneron, a biotechnology R&D and spin out company from the University of South Florida, US, will enter into an R&D agreement with LifeCell, a service provided by Asia Cryo-Cell Pvt. Ltd, India’s first cord blood bank, on Thursday.
Although refusing to divulge exact details on the agreement prior to the official announcement on Thursday, Mr Prasad Mangipudi, vice-president, marketing, LifeCell, said, "Saneron will be bringing patented stem cell technology to LifeCell and will be focusing on R&D, that would involve clinical trials among other things. The R&D centre of Saneron will be based in Chennai next to our headquarters. The stem cell industry has the potential to transform the Indian healthcare industry. In the future you will see the end of procedures like open heart surgery, because one will be able to use stem cell injections instead."
Saneron, a company which focuses on neurological and cardiac cell therapy, is likely to use LifeCell’s state-of-the-art stem cell processing and banking facility that was set up with an investment of Rs 14 crores in the outskirts of Chennai, for research purposes since the facility conforms to the standards of American Association of Blood Banks and US FDA.
The facility has a capacity to store over one lakh samples and is equipped with a trained technical team. LifeCell has enrolled 1,000 expectant parents for banking the cord blood stem cells, at this facility.
In November this year, GE Healthcare and Saneron announced an R&D agreement to optimise GE Healthcare’s Ficoll-Paque for the isolation of stem cells from umbilical cord blood. Cord blood, which is discarded after childbirth, is a rich source of stem cells, which can be harvested and cryo preserved to be used for treating more than 75 serious ailments.
Saneron has developed a proprietary processing technique for the isolation of a heterogeneous population of cells from umbilical cord blood that has shown promising results in pre-clinical studies of stroke, myocardial infarction, spinal cord injury, and Lou Gehrig’s disease.
Although refusing to divulge exact details on the agreement prior to the official announcement on Thursday, Mr Prasad Mangipudi, vice-president, marketing, LifeCell, said, "Saneron will be bringing patented stem cell technology to LifeCell and will be focusing on R&D, that would involve clinical trials among other things. The R&D centre of Saneron will be based in Chennai next to our headquarters. The stem cell industry has the potential to transform the Indian healthcare industry. In the future you will see the end of procedures like open heart surgery, because one will be able to use stem cell injections instead."
Saneron, a company which focuses on neurological and cardiac cell therapy, is likely to use LifeCell’s state-of-the-art stem cell processing and banking facility that was set up with an investment of Rs 14 crores in the outskirts of Chennai, for research purposes since the facility conforms to the standards of American Association of Blood Banks and US FDA.
The facility has a capacity to store over one lakh samples and is equipped with a trained technical team. LifeCell has enrolled 1,000 expectant parents for banking the cord blood stem cells, at this facility.
In November this year, GE Healthcare and Saneron announced an R&D agreement to optimise GE Healthcare’s Ficoll-Paque for the isolation of stem cells from umbilical cord blood. Cord blood, which is discarded after childbirth, is a rich source of stem cells, which can be harvested and cryo preserved to be used for treating more than 75 serious ailments.
Saneron has developed a proprietary processing technique for the isolation of a heterogeneous population of cells from umbilical cord blood that has shown promising results in pre-clinical studies of stroke, myocardial infarction, spinal cord injury, and Lou Gehrig’s disease.